HSP90B2P and cancer: Studies have shown that a variety of HSP inhibitors demonstrate potential therapeutic efficacy in cancer treatment, potentially by disrupting the ATPase activity of HSPs within cancer cells, thereby blocking oncogenic pathways and leading to apoptosis or loss of proliferative capacity in cancer cells [3, 4, 34, 35].